Pfizer Files Supplemental Proxy Materials for 2025
Ticker: PFE · Form: DEFA14A · Filed: Apr 7, 2025 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | DEFA14A |
| Filed Date | Apr 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-engagement, sec-filing
Related Tickers: PFE
TL;DR
Pfizer dropped more proxy docs for 2025 shareholder talks, no fee needed.
AI Summary
Pfizer Inc. filed a Definitive Additional Materials proxy statement on April 7, 2025, related to its 2025 shareholder engagement. This filing is supplemental to its primary proxy statement and indicates no fee was required for this submission.
Why It Matters
This filing provides additional information to shareholders regarding Pfizer's 2025 proxy season, impacting how shareholders vote on company matters.
Risk Assessment
Risk Level: low — This is a routine supplemental proxy filing with no immediate financial implications or significant new disclosures.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- 0000078003-25-000083.txt (document) — Accession Number
- 20250407 (date) — Filing Date
FAQ
What type of filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' for Pfizer Inc.
When was this filing made?
The filing was made on April 7, 2025.
What is the purpose of this filing?
This is a supplemental proxy statement to provide additional information to shareholders for the 2025 proxy season.
Was there a filing fee associated with this document?
No, the filing indicates 'No fee required'.
What is Pfizer's standard industrial classification?
Pfizer Inc.'s Standard Industrial Classification is 'Pharmaceutical Preparations [2834]'.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 7, 2025 regarding PFIZER INC (PFE).